NCT06692894Recruiting
Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
Defining Inflammatory Biomarkers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
Source: ClinicalTrials.gov · Last updated 3 Feb 2026
Brief summary (registry, in English)
Why Is This Research Study Being Conducted? * The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke. * Researchers also want to see if certain proteins related to inflammation in the body can help predict these heart issues in MDS patients. * By understanding this better, researchers hope to find new ways to detect and manage heart disease risks in people with MDS
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 14 Nov 2024
- Start date
- 5 Nov 2024
- Primary completion date
- Nov 2027
- Lead sponsor
- University of Vermont
- Diseases
- Myelodysplastic syndromes
- NCT number
- NCT06692894
What you commit to
- Study type: Observational
- Planned participants: 30
- From 5 Nov 2024 to the primary completion date, Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Hematopoietic stem cell transplantation expected within 6 months
Other
- Cases meeting 2022 WHO criteria of MDS with excess blasts 2 as initial diagnosis
Who the study is looking for
- Age ≥18 years
- Histologically confirmed diagnosis of MDS by bone marrow biopsy morphology, using the 2022 World Health Organization (WHO) classification for myeloid neoplasms
- Eastern Cooperative Oncology Group (ECOG) performance status ≤3
- Expected survival of at least 6 months
- Ability to provide consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Vermont Coordinator of this site? Confirm its status | Burlington | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.